Persefoni Kritikou Selected Research

HHS 5

3/2016

A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Persefoni Kritikou Research Topics

Disease

1	Hemophilia A (Haemophilia) 04/2018
1	Hemorrhage 04/2018
1	Bone Diseases (Bone Disease) 01/2017
1	Neoplasms (Cancer) 01/2017
1	Neoplasm Metastasis (Metastasis) 01/2017
1	Sudden Infant Death (SID) 03/2016
1	Breast Neoplasms (Breast Cancer) 03/2016
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2016

Drug/Important Bio-Agent (IBA)

1	Factor VIII (Coagulation Factor VIII)IBA 04/2018
1	Zoledronic Acid (Zometa)FDA Link 01/2017
1	Denosumab FDA Link 01/2017
1	Trastuzumab (Herceptin)FDA Link 03/2016
1	HHS 5IBA 03/2016
1	Rituximab (Mabthera)FDA Link 01/2016

Therapy/Procedure

1	Injections 04/2018
1	Intravenous Infusions 01/2017
1	Subcutaneous Injections 01/2017